Quest Partners LLC Takes $81,000 Position in Immunome, Inc. (NASDAQ:IMNM)

Quest Partners LLC purchased a new position in shares of Immunome, Inc. (NASDAQ:IMNM) during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 6,669 shares of the company’s stock, valued at approximately $81,000.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in IMNM. EntryPoint Capital LLC raised its stake in shares of Immunome by 21,864.0% during the 1st quarter. EntryPoint Capital LLC now owns 5,491 shares of the company’s stock worth $136,000 after buying an additional 5,466 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank purchased a new stake in Immunome in the 2nd quarter worth $97,000. Arizona State Retirement System increased its holdings in Immunome by 9.2% in the 2nd quarter. Arizona State Retirement System now owns 10,862 shares of the company’s stock worth $131,000 after acquiring an additional 918 shares in the last quarter. Jump Financial LLC acquired a new position in Immunome during the fourth quarter worth $172,000. Finally, Sequoia Financial Advisors LLC purchased a new position in Immunome during the second quarter valued at $206,000. Institutional investors and hedge funds own 44.58% of the company’s stock.

Analysts Set New Price Targets

A number of analysts have recently commented on IMNM shares. Wedbush reissued an “outperform” rating and set a $33.00 target price on shares of Immunome in a research note on Tuesday, August 13th. Piper Sandler cut their price objective on Immunome from $27.00 to $23.00 and set an “overweight” rating for the company in a research note on Tuesday, August 13th. Six investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock has a consensus rating of “Buy” and an average target price of $29.00.

Immunome Stock Down 2.5 %

Shares of NASDAQ IMNM opened at $15.40 on Wednesday. The firm has a 50-day simple moving average of $14.34 and a 200-day simple moving average of $16.32. The stock has a market capitalization of $923.52 million, a price-to-earnings ratio of -2.04 and a beta of 1.77. Immunome, Inc. has a 52 week low of $6.65 and a 52 week high of $30.96.

Immunome (NASDAQ:IMNM) last released its quarterly earnings data on Monday, August 12th. The company reported ($0.49) EPS for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.11). The business had revenue of $2.36 million during the quarter, compared to analyst estimates of $2.62 million. Immunome had a negative net margin of 2,435.02% and a negative return on equity of 38.19%. As a group, equities research analysts expect that Immunome, Inc. will post -1.92 EPS for the current year.

Insider Activity at Immunome

In other news, Director Jean Jacques Bienaime purchased 7,000 shares of the stock in a transaction dated Friday, August 16th. The shares were purchased at an average price of $13.94 per share, with a total value of $97,580.00. Following the transaction, the director now owns 16,615 shares in the company, valued at approximately $231,613.10. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In related news, insider Jack Higgins sold 3,524 shares of the stock in a transaction that occurred on Thursday, August 15th. The stock was sold at an average price of $13.93, for a total value of $49,089.32. Following the completion of the transaction, the insider now directly owns 16,000 shares in the company, valued at $222,880. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Jean Jacques Bienaime bought 7,000 shares of the business’s stock in a transaction on Friday, August 16th. The shares were acquired at an average cost of $13.94 per share, with a total value of $97,580.00. Following the purchase, the director now owns 16,615 shares of the company’s stock, valued at $231,613.10. The disclosure for this purchase can be found here. Insiders own 8.60% of the company’s stock.

Immunome Profile

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.